Pre-made Relfovetmab benchmark antibody ( Feline Whole mAb, anti-NGFB/NGF therapeutic antibody, Anti-HSAN5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Relfovetmab biosimilar, Feline Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-477-1mg	1mg	3090
GMP-Bios-ab-477-10mg	10mg	Inquiry
GMP-Bios-ab-477-100mg	100mg	Inquiry
GMP-Bios-ab-477-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Relfovetmab biosimilar, Feline Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody
INN Name	Relfovetmab
Target	NGF
Format	Feline Whole mAb
Derivation	Felinized
Species Reactivity	Feline
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Unknown
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	na
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	na
Development Tech	na